US Patent

US9789270 — Inhalation therapy device comprising an ampoule for storing a medicament to be nebulized

Formulation · Assigned to PARI Pharma GmbH · Expires 2030-10-30 · 4y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an inhalation therapy device that nebulizes a medicament, such as a fluid containing glycopyrrolate, into an aerosol for inhalation.

USPTO Abstract

An inhalation therapy device includes an atomizer for atomizing a drug which is advantageously present in the form of a fluid into an atomization chamber so that an aerosol or mist is provided in the atomization chamber. The patient or user can inhale the aerosol produced by the atomizer from the atomization chamber via a mouthpiece. The ampoule is inserted into an ampoule holder holding the fluid-containing ampoule. The inhalation therapy device also includes an opening unit for opening the fluid-containing ampoule. The ampoule holder advantageously includes a first part, disposed displaceably in relation to the opening unit, thereby allowing an ampoule present in the ampoule holder to be displaced in the direction of the opening unit.

Drugs covered by this patent

Patent Metadata

Patent number
US9789270
Jurisdiction
US
Classification
Formulation
Expires
2030-10-30
Drug substance claim
No
Drug product claim
Yes
Assignee
PARI Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.